Research programme: eye disorder and wound therapeutics - NuvOx Pharma/Undisclosed companies
Latest Information Update: 27 May 2016
At a glance
- Originator NuvOx Pharma; Unknown
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Eye disorders
- Research Wounds
Most Recent Events
- 27 May 2016 Early research in Wounds in USA (unspecified route)
- 27 May 2016 Preclinical trials in Eye disorders in USA (unspecified route)